Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Igc Pharma Inc (NY: IGC ) 0.3541 +0.0041 (+1.17%) Official Closing Price Updated: 8:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 2,732,455 Open 0.3500 Bid (Size) 0.4160 (5) Ask (Size) 0.4199 (21) Prev. Close 0.3500 Today's Range 0.3383 - 0.3541 52wk Range 0.2501 - 0.9099 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 12 Health Care Stocks Moving In Friday's After-Market Session September 27, 2024 Via Benzinga InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing IGC-AD1’s Potential to Effectively Target Tau Pathology, Improve Cognitive Function in Alzheimer’s September 18, 2024 Via Investor Brand Network Topics Artificial Intelligence Intellectual Property Exposures Artificial Intelligence Intellectual Property Performance YTD +28.30% +28.30% 1 Month -0.56% -0.56% 3 Month -18.37% -18.37% 6 Month -25.61% -25.61% 1 Year +1.46% +1.46% More News Read More IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment September 18, 2024 From IGC Pharma, Inc. Via Business Wire The Analyst Verdict: IGC Pharma In The Eyes Of 4 Experts September 03, 2024 Via Benzinga InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Advances IGC-AD1 Research to Potentially Deliver ‘Breakthrough Treatment’ in Alzheimer’s Disease September 04, 2024 Via Investor Brand Network Topics Artificial Intelligence Intellectual Property Exposures Artificial Intelligence Intellectual Property Product Safety IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease September 04, 2024 From IGC Pharma, Inc. Via Business Wire BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Announces Stockholders’ Approval of All Disclosed Proposals at 2024 Annual Meeting August 27, 2024 Via Investor Brand Network Topics Artificial Intelligence Intellectual Property Regulatory Compliance Exposures Artificial Intelligence Intellectual Property Legal IGC Announces Results of its 2024 Annual Stockholders Meeting August 26, 2024 From IGC Pharma, Inc. Via Business Wire InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Preclinical Research Evaluating New Molecule IGC-1C in Treatment of Alzheimer’s Disease August 22, 2024 Via Investor Brand Network Topics Artificial Intelligence Intellectual Property Exposures Artificial Intelligence Intellectual Property IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease August 22, 2024 From IGC Pharma, Inc. Via Business Wire InvestorNewsBreaks – IGC Pharma Inc.’s (NYSE American: IGC) AI-Driven Approach Reveals ‘Promising Opportunity’ for IGC-1A to Be a Potential GLP-1 Agonist August 20, 2024 Via Investor Brand Network Topics Artificial Intelligence Intellectual Property Exposures Artificial Intelligence Intellectual Property IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist August 20, 2024 From IGC Pharma Via Business Wire IGC Stock Earnings: IGC Pharma Beats EPS, Misses Revenue for Q1 2025 August 12, 2024 Via InvestorPlace BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Q1 2025 Financial, Operational Results Report August 09, 2024 Via Investor Brand Network Topics Artificial Intelligence Intellectual Property Exposures Artificial Intelligence Intellectual Property IGC Pharma Revenue Declines 51% YoY Due To Completion Of Its Legacy Project In India, Highlights Important Milestones In Alzheimer's Research August 09, 2024 Via Benzinga IGC Pharma Reports First Quarter Fiscal 2025 Results August 08, 2024 From IGC Pharma, Inc. Via Business Wire InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives ‘Buy’ Recommendation in AGP’s Analyst Coverage Research Report July 18, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target July 18, 2024 From IGC Pharma, Inc. Via Business Wire BioMedNewsBreaks — IGC Pharma Inc.’s (NYSE American: IGC) TGR-63 Demonstrates Blood-Brain Barrier Permeability in Preliminary Findings July 09, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile July 09, 2024 From IGC Pharma, Inc. Via Business Wire BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Positive Data from TGR-63 Preclinical Studies June 26, 2024 Via Investor Brand Network Topics Artificial Intelligence Intellectual Property Exposures Artificial Intelligence Intellectual Property InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Financial Report for Fiscal Year June 25, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease June 25, 2024 From IGC Pharma, Inc. Via Business Wire Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday June 25, 2024 Via InvestorPlace IGC Stock Earnings: IGC Pharma Meets EPS, Beats Revenue for Q4 2024 June 24, 2024 Via InvestorPlace Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.